|Depositor:||Wellcome Trust Sanger Institute|
|Cell line name:||WTSIi066-B|
|Cell line alternative names:||HPSI0613i-febc_2|
|Derivation country:||United Kingdom|
|From the same donor:||WTSIi066-A|
Primary cell type: Fibroblast Primary cell line vendor: Cambridge BioResource Location of primary tissue procurement: Zone of skin
Vector type: Non-integrating Vector: Sendai virus Gene list:
Is the reprogramming vector detectable: Unknown
Xeno free conditions: no Derived under gmp: no Available as clinical grade: no
Medium: - Passage method: EDTA Matrix: Vitronectin CO2 concentration: 5% O2 concentration: 20% Temperature: 37C
Analysis of Undifferentiated Cells
Marker expression: Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles SOX2 Yes POU5F1 (OCT-4) Yes NANOG Yes PluriTest: Pluripotency score: 34.568
Novelty score: 1.195
Microarray data: https://www.ebi.ac.uk/ega/datasets/EGAD00010000775
HPSI-febc.pluritest.pluripoten_qvlYz9F.png - pluripotency image
HPSI-febc.pluritest.novelty_sc_VRZF8ck.png - novelty image
The PluriTest is a pluripotency assessment based on DNA microarray data, which considers the genome-wide expression profile of the sample (www.nature.com/nmeth/journal/v8/n4/full/nmeth.1580.html).
PluriTest scores should be assessed in the context of the empirical distribution of pluripotent and somatic samples used to construct and validate PluriTest (e.g. Exemplary use of PluriTest). The training set of iPSC clustered with pluripotency score > 25 and novelty score < 1.67 with 98% sensitivity and 100% specificity. Cell lines with pluritest scores > 10 also cluster with the PluriTest training data set with high sensitivy and specificity.
Microbiology / Virus Screening
HIV 1: Negative HIV 2: Negative Hepatitis B: Negative Hepatitis C: Negative Mycoplasma: Negative
Inoculation for microbiological growth: No Contaminants Detected Mycoplasma: Not Detected Viability: Viable post-cryopreservation
STR/Fingerprinting: A 16 allele profile has been recorded and data is available upon request, after cell line purchase.